Glenn Schulman, PharmD, MPH

Glenn has served as our VP, Head of Investor Relations and Corporate Communications since April 2024. Dr. Schulman has over 20 years of experience in the biotech industry focused on investor and public relations, corporate strategy, medical and corporate communications. Prior to joining IN8bio, Glenn was responsible for leading IR and Corporate Communications at multiple NASDAQ-listed companies including ProKidney Corp., Aurinia Pharmaceuticals, Achillion Pharmaceuticals, and CuraGen Corp. Dr. Schulman’s expertise spans the drug development life cycle from discovery through the commercialization of novel small molecule, biologic, and cell therapy candidates. Dr. Schulman also worked as a pharmacist in both hospital and retail settings for 15 years. Dr. Schulman attained his bachelor’s degree from Philadelphia College of Pharmacy and his Doctor of Pharmacy degree from Rutger’s University. Dr. Schulman received his Master Public Health, Health Management degree from Yale University.